Sysmex Europe’s Post

A bit more news on our work on antimicrobial stewardship with this publication: https://lnkd.in/ekq2XE_q In this paper we simulate the processing of blood cultures, which are essential for treating patients with sepsis and bloodstream infections, through a laboratory workflow. Based on data collected by observing lab staff as well as historical information, we were able to develop a model that can help labs identify areas to improve for the future. This is very much the first step for us, with the aim being for these types of models to inform decisions about the prescription of antibiotics in the future. #antimicrobialresistance #simulation #modelling

AI to identify drug-resistant typhoid-like infection One of the challenges facing healthcare workers is the ability to distinguish rapidly between organisms that can be treated with first-line drugs and those that are resistant to treatment. Conventional testing can take several days, requiring bacteria to be cultured, tested against various antimicrobial treatments, and analysed by a laboratory technician or by machine. This delay often results in patients being treated with an inappropriate drug, which can lead to more serious outcomes and, potentially, further drive drug resistance. In research published in Nature Communications, a team of researchers developed a machine-learning tool capable of identifying from microscopy images Salmonella Typhimurium bacteria that are resistant to the first-line antibiotic ciprofloxacin – even without testing the bacteria against the drug. The team used high-resolution microscopy to examine S. Typhimurium isolates exposed to increasing concentrations of ciprofloxacin and identified the five most important imaging features for distinguishing between resistant and susceptible isolates. They then trained and tested machine-learning algorithm to recognise these features using imaging data from 16 samples. The algorithm was able to correctly predict in each case whether or not bacteria were susceptible or resistant to ciprofloxacin without the need for the bacteria to be exposed to the drug. This was the case for isolates cultured for just six hours, compared to the usual 24 hours to culture a sample in the presence of antibiotic. #sciencenewshighlights #ScienceMission https://lnkd.in/gau_M4jb

The rise of bacteriophage therapy as an alternative to antibiotics is one trend in microbiology that grabbed my attention without permission😎 When microorganisms evolve to resist antibiotics, antimicrobial resistance (AMR) occurs, threatening decades of medical progress. AMR leads to longer hospital stays, higher costs, and increased mortality, making it a critical issue. Bacteriophage therapy uses bacteriophages: viruses that target and kill specific bacteria, to treat infections that no longer respond to conventional antibiotics. What excites me about this therapy is its precision: it targets harmful bacteria without affecting beneficial microbes or human cells, offering a safer treatment option. You may wonder why phages aren’t as widely used as antibiotics. One major reason is their narrow host range. Unlike antibiotics that can kill a wide range of bacterial species, phages typically only infect and kill one specific type of bacteria. I’m eager to see how bacteriophage therapy, alongside ongoing AMR research, will shape the future of microbiology and contribute to new treatment solutions. #MicrobiologyAndFoodScience #IndustryTrends #Day8of25 #BacteriophageTherapy #AMR

🌟 Innovations in Bacterial Resistance Testing: ZOI, MIC, and Beyond 🌟 As antibiotic resistance continues to challenge healthcare globally, accurate and innovative testing methods are crucial for developing effective treatments. At Microbe Investigation Switzerland (MIS), we're at the forefront of this fight, offering comprehensive testing services that include Zone of Inhibition (ZOI), Minimum Inhibitory Concentration (MIC) assessments, and beyond. 🦠🔍 Our cutting-edge technologies ensure precise and reliable results, helping researchers and developers create effective antimicrobial products. Whether you're in the early stages of drug development or seeking to validate your latest formulations, our expert team is here to support your needs every step of the way. 💡🔬 Discover more about our innovative approaches and how we can assist you in your bacterial resistance testing journey. Visit our website for detailed insights: Innovations in Bacterial Resistance Testing: ZOI, MIC, and Beyond 🌐 #BacterialResistance #AntimicrobialTesting #Innovations #MicrobialInvestigations #MIS #ZoneOfInhibition #MinimumInhibitoryConcentration #DrugDevelopment #TestingServices #ResearchAndDevelopment #AntibacterialTesting #ScienceInnovation

🔬 Anti-Virulence Therapy: An Alternate to Conventional Antibiotics! 🔬 I am excited to share our latest research; our team at Freie Universität Berlin has made groundbreaking strides in the quest for novel anti-infective treatments. Our findings were acknowledged and recently published in the prestigious journal, Nature Communications. The world is grappling with a critical shortage of novel antibiotics and the escalating threat of antimicrobial resistance (AMR). Realizing the urgency of the situation, we have developed targeted small molecules called Pore-blockers (PB) that specifically inhibit the deadly virulence factor of many gram-positive bacteria known as CDC, a group of pore-forming toxins. Thus, PB molecules block the pore-forming toxins, rendering the bacteria feeble. We have successfully validated our findings against multiple CDC toxins and have laid the foundation for a transformative anti-virulence therapy. This is just the beginning of our journey. With unwavering determination, our scientific team is committed to optimize our lead compound and further advance our testing. Together, we are forging ahead in the pursuit of innovative solutions to combat infectious diseases and safeguard global health. #AntiInfectives #AMRCrisis #InfectiousDiseases #NatureCommunications #FreieUniversityBerlin #AntiVirulenceTherapy #DrugDevelopment https://lnkd.in/ejfVwgfi

🌍 Did you know that antibiotic-resistant bacteria claim 700,000 lives globally each year? 🦠 If left unchecked, that number could skyrocket. As we mark World Antimicrobial Resistance Awareness Week 2024 (18-24 November), the spotlight is on this pressing global health challenge: antimicrobial resistance against antibiotics. 💊 With a €1 million grant from JPIAMR, Professor Coen van Hasselt and his team are breaking new ground in developing smart antibiotic combinations to combat bacteria more effectively and slow the development of resistance. By harnessing cutting-edge computer modelling 🖥️ and international collaboration, they aim to revolutionise how we combat resistant infections while minimising harmful side effects. The project not only promises life-saving treatment options but also lays the foundation for a toolbox that empowers pharmaceutical developers to stay ahead in this evolutionary arms race. Read more: https://lnkd.in/euru9cVx #WorldAntimicrobialAwarenessWeek #AntimicrobialResistance #InnovationInHealth #LeidenUniversity #GlobalHealth #WAAW Sebastian Wicha, FESCMID, Joseph Standing, Marchand Sandrine, Oana Ciofu, Linda Aulin! Universität Hamburg Université de Poitiers UCL Article by: Rianne Lindhout

🌍 Tackling Antimicrobial Resistance: A Call to Innovate and Collaborate 🦠 The latest WHO report on antibacterial agents in development highlights both progress and pressing challenges in the fight against antimicrobial resistance (AMR). While the number of antibacterial agents in clinical development has risen from 80 in 2021 to 97 in 2023, innovation remains critically lacking. 🔑 Key Insights_ Only 12 out of 32 antibiotics under development for WHO's priority pathogens are innovative. Critical gaps exist in products for children, oral formulations for outpatients, and treatments for rising drug resistance. Non-traditional agents like bacteriophages, antibodies, and microbiome-modulating therapies show promise but require more clinical exploration. Since 2017, only 2 of 13 newly approved antibiotics represent new chemical classes—a reminder of the complexity of developing effective, safe antibacterials. AMR poses a global health threat, exacerbated by overuse of antimicrobials and limited access in many regions. The need for equitable access to these life-saving agents, especially in low- and middle-income countries, cannot be overstated. The report emphasizes the importance of: 1️⃣ Increased collaboration and transparency in R&D pipelines. 2️⃣ Support for innovative approaches to address Gram-negative bacteria. 3️⃣ Ensuring equitable access to diagnostics and treatment for all. Let’s work together to ensure that life-saving innovations not only reach the pipeline but also the people who need them most. #AntimicrobialResistance #AMR #GlobalHealth #Innovation #WHO #PublicHealth #Equity #Sustainability

🚀 Revolutionizing Antibiotic Resistance Detection! 🦠 The global battle against antibiotic-resistant bacteria, especially against β-lactam antibiotics, has reached a critical juncture. A groundbreaking near-infrared fluorogenic probe has emerged, enhancing the imaging of bacterial infections in live animals. 🔍 Key Highlights: - Enhanced Sensitivity: This innovative probe targets the β-lactam-hydrolyzing enzyme, significantly improving detection sensitivity—over 1500-fold compared to traditional methods! - Market Access Impact: Streamlining drug development and regulatory approval processes could lead to faster access to new treatments for healthcare providers and patients alike. - Transformative Potential: With superior imaging capabilities, this technology promises better management of resistant infections—addressing a pressing public health crisis. As we integrate this cutting-edge technology into clinical practice, we move closer to effective solutions for antibiotic resistance. 👉 Click the link for more insights on this transformative advancement! #AntibacterialTreatments #AntibioticResistance #HealthTechnologyAssessment #HealthcareInnovation #MedicalResearch #PublicHealth #Publications #MarketAccess #MarketAccessToday

The increase in bacteria resistant to multiple drugs has diminished the effectiveness of conventional antibiotics, highlighting the necessity for alternative treatments like bacteriophages. However, there is a lack of information regarding phages that target Klebsiella pneumoniae. This analysis delves into the present status of phage therapy for K. pneumoniae infections, encompassing treatment modalities, obstacles, emerging technologies, safety measures, efficacy, regulatory aspects, and future pathways for enhancing phage therapy to counter multidrug resistance. Enhancing phage technology is crucial in addressing the menace posed by multidrug-resistant K. pneumoniae. #PhageTherapy #AntibioticResistance https://buff.ly/480wuBG